Drug Pipeline

Sacituzumab tirumotecan Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
93
Active Studies
44
Recruiting
38
Phase 3
10
Top Sponsors
28
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer…
Trial sites expanded: 77 -> 89 locations
2026-06-09 NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer…
Trial sites expanded: 42 -> 50 locations
2026-06-09 NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's…
Trial sites expanded: 62 -> 74 locations
2026-06-09 NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab…
Trial sites expanded: 115 -> 125 locations
2026-06-06 NCT07007559
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in…
Trial sites expanded: 32 -> 44 locations
2026-06-02 NCT07341100
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on…
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-02 NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab…
Trial sites expanded: 107 -> 115 locations
2026-05-30 NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not…
Trial sites expanded: 293 -> 297 locations
2026-05-30 NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer…
Trial sites expanded: 38 -> 42 locations
2026-05-30 NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer…
Trial sites expanded: 60 -> 77 locations
2026-05-28 NCT06459180
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-28 NCT04345913
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
date change Completion pushed: 2026-05-07 -> 2027-05-31
2026-05-27 NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer…
Trial sites expanded: 12 -> 18 locations
2026-05-27 NCT07461454
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Recruitment opened
2026-05-23 NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer…
Trial sites expanded: 30 -> 38 locations
2026-05-23 NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast…
Trial sites expanded: 287 -> 291 locations
2026-05-23 NCT06305754
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-23 NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer…
Trial sites expanded: 50 -> 60 locations
2026-05-23 NCT07173751
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative…
Trial sites expanded: 83 -> 104 locations
2026-05-23 NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab…
Trial sites expanded: 96 -> 107 locations
Showing 20 of 28 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-10 NCT07639086 Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy Phase 2 Not Yet Recruiting
2026-06-05 NCT07628504 Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk… Phase 3 Not Yet Recruiting
2026-06-03 NCT07622186 A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer… Phase 2 Not Yet Recruiting
2026-06-03 NCT07622706 Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung… Phase 2 Not Yet Recruiting
2026-06-03 NCT07623577 Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases Phase 2 Recruiting
Active Studies by Phase
Phase 3
38
Phase 2
38
Phase 1/2
10
Phase 1
5
Not specified
2
Active Trials — top 25 of 93
NCT IDTitleConditionStatus
Phase 3
NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination… Non-Small Cell Lung Cancer Recruiting
NCT06435429 A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in… Metastatic HER2-positive Breast Cancer Recruiting
NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Metastatic Breast Cancer Recruiting
NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable… Triple Negative Breast Cancer Recruiting
NCT06670196 A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With… Non-Small Cell Lung Cancer Recruiting
NCT07071337 A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With… Metastatic Breast Cancer Recruiting
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab… Non Small Cell Lung Cancer Recruiting
NCT07173751 ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative… Breast Neoplasms Recruiting
NCT07461454 YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer Locally Advanced or Metastatic Breast Cancer Recruiting
NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… Triple Negative Breast Neoplasms Recruiting
NCT06952504 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… Endometrial Cancer Recruiting
NCT06170788 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab… Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With… Breast Neoplasms Recruiting
NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not… Triple-Negative Breast Cancer Recruiting
NCT06422143 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in… Non-small Cell Lung Cancer Recruiting
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870)… Ovarian Cancer Recruiting
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast… Breast Neoplasms Recruiting
NCT07185997 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's… Non-Small-Cell Lung Cancer Recruiting
NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… Cervical Cancer Recruiting
NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… Ovarian Neoplasms Recruiting
NCT07419295 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer… Bladder Cancer Recruiting
NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or… Triple Negative Breast Cancer Active, Not Recruiting
NCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer… Metastatic Breast Cancer Active, Not Recruiting
NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic… Gastroesophageal Cancer Active, Not Recruiting
NCT06132958 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial… Endometrial Cancer Active, Not Recruiting
Sponsors Running Sacituzumab tirumotecan Trials
Disease Areas
Get alerts when Sacituzumab tirumotecan trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free